Gracell Biotechnologies Stock Forecast, Price & News

Gracell Biotechnologies (NASDAQ:GRCL) Frequently Asked Questions

Is Gracell Biotechnologies a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Gracell Biotechnologies stock.
View analyst ratings for Gracell Biotechnologies or view top-rated stocks.

Are investors shorting Gracell Biotechnologies?

Gracell Biotechnologies saw a decrease in short interest in October. As of October 29th, there was short interest totaling 634,200 shares, a decrease of 23.0% from the October 14th total of 823,400 shares. Based on an average daily trading volume, of 81,200 shares, the short-interest ratio is currently 7.8 days. Currently, 1.1% of the shares of the company are short sold.
View Gracell Biotechnologies' Short Interest.

When is Gracell Biotechnologies' next earnings date?

Gracell Biotechnologies is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Gracell Biotechnologies.

How were Gracell Biotechnologies' earnings last quarter?

Gracell Biotechnologies Inc. (NASDAQ:GRCL) posted its quarterly earnings results on Sunday, November, 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.18.
View Gracell Biotechnologies' earnings history.

What price target have analysts set for GRCL?

4 brokers have issued 12 month price targets for Gracell Biotechnologies' stock. Their forecasts range from $30.00 to $40.00. On average, they expect Gracell Biotechnologies' share price to reach $34.50 in the next year. This suggests a possible upside of 404.4% from the stock's current price.
View analysts' price targets for Gracell Biotechnologies or view top-rated stocks among Wall Street analysts.

Who are Gracell Biotechnologies' key executives?

Gracell Biotechnologies' management team includes the following people:

• Dr. Wei Cao, Founder, Chairman & CEO (Age 62)
• Dr. Yili Xie M.B.A., Ph.D., Chief Financial Officer (Age 50)
• Dr. Yajin Ni, Chief Technology Officer
• Dr. Martina A. Sersch M.D., Ph.D., Chief Medical Officer (Age 48)

Who are some of Gracell Biotechnologies' key competitors?

Some companies that are related to Gracell Biotechnologies include Agios Pharmaceuticals (AGIO), Global Blood Therapeutics (GBT), Erasca (ERAS), Cassava Sciences (SAVA), Ironwood Pharmaceuticals (IRWD), Atai Life Sciences (ATAI), Turning Point Therapeutics (TPTX), Dynavax Technologies (DVAX), Morphic (MORF), Enanta Pharmaceuticals (ENTA), IVERIC bio (ISEE), Kadmon (KDMN), Bicycle Therapeutics (BCYC), Travere Therapeutics (TVTX) and Supernus Pharmaceuticals (SUPN).
View all of GRCL's competitors.

When did Gracell Biotechnologies IPO?

(GRCL) raised $150 million in an initial public offering (IPO) on Friday, January 8th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities acted as the underwriters for the IPO.

What is Gracell Biotechnologies' stock symbol?

Gracell Biotechnologies trades on the NASDAQ under the ticker symbol "GRCL."

Who are Gracell Biotechnologies' major shareholders?

Gracell Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Temasek Holdings Private Ltd (14.73%), Wellington Management Group LLP (7.38%), Viking Global Investors LP (2.02%), Morgan Stanley (1.43%), BlackRock Inc. (1.39%) and Capital International Sarl (0.24%).

Which institutional investors are selling Gracell Biotechnologies stock?

GRCL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Citadel Advisors LLC, and Marshall Wace LLP.

Which institutional investors are buying Gracell Biotechnologies stock?

GRCL stock was acquired by a variety of institutional investors in the last quarter, including Temasek Holdings Private Ltd, Wellington Management Group LLP, Viking Global Investors LP, Vident Investment Advisory LLC, Capital International Sarl, and Daiwa Securities Group Inc..

How do I buy shares of Gracell Biotechnologies?

Shares of GRCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gracell Biotechnologies' stock price today?

One share of GRCL stock can currently be purchased for approximately $6.84.

How much money does Gracell Biotechnologies make?

Gracell Biotechnologies has a market capitalization of $461.70 million.

How many employees does Gracell Biotechnologies have?

Gracell Biotechnologies employs 2,020 workers across the globe.

What is Gracell Biotechnologies' official website?

The official website for Gracell Biotechnologies is www.gracellbio.com.

How can I contact Gracell Biotechnologies?

The company can be reached via phone at 86-512-6262-6701 or via email at [email protected].